Introduction
Platelets are central to the physiologic process of hemostasis and pathologic process of thrombosis. The mechanisms underlying the role of platelets in these processes are highly complex, integrated, and regulated, involving the interaction of multiple surface platelet receptors, including the glycoprotein Ib-IX-V (GPIb-IX-V) complex, ␣ IIb ␤ 3 , and glycoprotein VI/Fc receptor gamma chain (GPVI/FcR-␥ chain) complex with subendothelial proteins, and plasma ligands. 3 The low-affinity immunoglobulin G (IgG) Fc receptor, Fc␥RIIa, and the collagen receptor GPVI/FcR-␥ chain complex are 2 IgG-bearing immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors expressed on the human platelet surface. These ITAM-containing receptors bear tandem ITAM motifs (D/ExYxxL/I-x 7 -YxxL/I) either within their cytoplasmic tails or within an associated protein and are the actual signal transducing element of the receptor. On receptor clustering, activation of receptor-associated tyrosine kinases of the Src family occurs, which phosphorylate the ITAM motif. The phosphorylated ITAM then serves as a docking site for Src-homology 2 (SH2) domain-containing adapter proteins and enzymes, including Syk protein-tyrosine kinase, thereby recruiting molecules to the membrane and to the proximity of their substrates, including phospholipase C␥ (PLC␥), the Ras activating enzyme, Sos and phosphoinositide 3-kinase (PI-3K). [4] [5] [6] In contrast to the GPVI/FcR-␥ chain complex, Fc␥RIIa is unique where the ligand binding domain and the intracellular ITAM are contained in the one polypeptide, whereas the GPVI/FcR-␥ chain complex consists of GPVI noncovalently associating with the ITAM-containing FcR-␥ chain. 7, 8 Fc␥RIIa is the sole Fc platelet receptor existing as a dimer with each molecule being a 40-kDa molecular weight (MW) type I membrane glycoprotein possessing 2 extracellular immunoglobulin domains that bind IgG (K D ϳ10 Ϫ6 ), a transmembrane domain, and an ITAMcontaining intracellular domain. The extracellular domain contains a polymorphism at amino acid position 131 (Arg/His) and has been implicated in immune complex-related diseases such as systemic lupus erythematosus. 9 In addition, in vitro and in vivo murine models have demonstrated that Fc␥RIIa is involved in heparininduced thrombocytopenia (HITS). 10 In vitro activation of platelet Fc␥RIIa via clustering with aggregated human IgG or activatory anti-Fc␥RIIa antibodies causes platelet activation, secretion, shape change, and aggregation through an ITAM signaling pathway. 11 Such tyrosine kinase-dependent activity pathways are regulated by phosphatases in which activity is dependent on immunoreceptor tyrosine-based inhibition motif (ITIM) sequences. Platelets also express several ITIM-containing surface receptors, including PECAM-1, signal regulatory protein ␣ (SIRP␣), and protein zero related (PZR). [12] [13] [14] PECAM-1 is a 130-kDa MW transmembrane protein member of the immunoglobulin-ITIM superfamily with an extracellular domain containing 6 Ig-domains, a transmembrane domain, and a dual ITIM-containing intracellular domain. 15, 16 It is now recognized that regulation of cell signaling involves a balance between activatory and inhibitory signals as observed in many immune cells. 17 In particular, the negative regulation of ITAM-containing receptors by their inhibitory counterparts, ITIMcontaining receptors, determines both the threshold and magnitude of activatory responses and corresponding cellular effects. For regulation of one receptor signaling pathway by another, a close physical proximity and coengagement between these receptors is required for induction of interactions between target substrates, adaptors, and effector molecules in their individual signaling pathways. Previous studies have defined physical associations of several platelet receptors, including GPIb␣ with Fc␥RIIa, GPIb␣ and the GPVI/FcR-␥ chain complex, GPIb␣ and protein-disulfide isomerase, and CD151 with integrin ␣ IIb ␤ 3 . [18] [19] [20] More importantly, a functional relationship has been demonstrated between the ITAMcontaining GPVI/FcR-␥ chain complex that is negatively regulated by the ITIM-containing PECAM-1 receptor on both murine and human platelets to down-modulate platelet-collagen interactions. 1, 2 It is therefore conceivable that PECAM-1 may also negatively regulate Fc␥RIIa in human platelets, particularly because platelets lack the inhibitory coreceptor, Fc␥RIIB, that is known to negatively regulate Fc␥RIIA in other cell types. However, the fact that ITIM-containing receptors are known to have different affinities for different ITAM-containing receptors, and, unlike the GPVI/FcR-␥ chain complex, the ITAM is associated with the ligand binding polypeptide of Fc␥RIIa, prompted us to investigate the possible existence of a physical and functional relationship between Fc␥RIIa and PECAM-1. The importance of Fc␥RIIa in both pathophysiologic conditions and healthy platelet function further necessitates these studies.
In light of evidence indicating the potential existence of a physical and functional relationship between platelet Fc␥RIIa and PECAM-1, we hypothesize that PECAM-1 negatively regulates Fc␥RIIa-mediated platelet responses through attenuation of signaling via the recruitment of protein-tyrosine phosphatases (PTPs) such as SHP-2 (Src homology 2-containing protein-tyrosine phosphatase 2) subsequent to the phosphorylation of the dual PECAM-1 ITIMs, resulting in dephosphorylation of important signaling effector and adaptor molecules involved in the Fc␥RIIa ITAMmediated signaling pathway. To address this hypothesis using in vitro studies, we investigated the physical proximity and possible colocalization of Fc␥RIIa and PECAM-1 on the surface of human platelets using distinct complementary biochemical techniques, flow cytometry, fluorescence resonance energy transfer (FRET), coimmunoprecipitation, and Western blot studies. We next examined the functional effect of PECAM-1 on Fc␥RIIa-mediated platelet aggregation induced by aggregated IgG, activatory antiFc␥RIIa antibody cross-linking, and heparin-induced thrombocytopenia antibody. Finally, we delineated the molecular signaling mechanisms that govern the above functional relationship by using immunoprecipitation/Western blot analysis to profile important protein-tyrosine phosphorylated signaling molecules in Fc␥RIIa and PECAM-1 signaling pathways.
These studies show for the first time that Fc␥RIIa and PECAM-1 are physically and functionally associated on the surface of human platelets. More importantly, they provide a greater insight into the function and regulation at the signaling level of the physiologically and pathophysiologically important sole platelet Fc receptor, Fc␥RIIa, and potential novel therapeutic targets.
Materials and methods

Aggregated human IgG
Human IgG (10 mg; Sigma Chemical, St Louis, MO) was aggregated as described previously. 18 
Monoclonal antibodies
The following monoclonal antibodies (mAbs) were used in this study: PECAM-1. 24, 25 ; VM16d mAb was kindly provided by Dr Michael Berndt (Monash University, Clayton, Victoria, Australia). 26 
Preparation and biotinylation of monoclonal antibody Fab fragments
Fab fragments were prepared for the following mAbs: PECAM-1.1, PECAM-1.2, PECAM-1.3, 2BD4, B2B1, 11B1, and IV.3 with the use of a standard protocol using Ficin as previously described. 27 Biotinylation of IV.3, PECAM-1.1, 2BD4, B2B1, and 11B1 Fab fragments was performed according to manufacturers' instructions.
Preparation of human platelets
Platelet-rich plasma (PRP) and washed platelets were prepared from freshly obtained human blood as previously described. 16 
Binding of aggregated human IgG to washed platelets
The binding of aggregated human IgG and IV.3 to human platelets was assessed as previously described. 18 Acquisition flow cytometry analysis was performed with an Epics XL-MCL (Beckman-Coulter, Fullerton, CA) using a platelet-specific fluorescein isothiocyanate (FITC) protocol with forward scatter (FSC), side scatter (SSC), and fluorescent parameters in log scale.
Aggregated human IgG-mediated platelet aggregation
Aggregated IgG induction of platelet aggregation mediated through Fc␥RIIa was analyzed using a Packs-4 Platelet Aggregation Chromogenic Kinetic System (Helena Laboratories, Beaumont, TX). For aggregated IgGmediated platelet aggregation, 225 g/mL aggregated IgG was added to 450 L washed platelets (3 ϫ 10 8 /mL) in Ringer-citrate-dextrose (RCD) pH 7.4. In blocking experiments, 10 g/mL final concentration of nonbiotinylated anti-Fc␥RIIa (IV.3 Fab), biotinylated anti-PECAM-1 (PECAM-1.1, 2BD4, and B2B1 Fab), and biotinylated anti-CD151 (11B1 Fab) was added to the washed platelets with stirring for 5 minutes, prior to the addition of aggregated IgG to induce platelet aggregation.
IV.3-mediated platelet aggregation
This assay system involves the simultaneous coengagement of Fc␥RIIa and PECAM-1 using optimal concentrations of biotinylated anti-Fc␥RIIa (IV.3) and biotinylated anti-PECAM-1 (2BD4 Fab) with cross-linking induced by the addition of Neutravidin (Pierce, Rockford, IL). Specificity control of Neutravidin to induce Fc␥RIIa-mediated aggregation through cross-linking of biotinylated IV.3 mAb was applied using biotinylated IV.3 mAb without the addition of Neutravidin. Anti-CD151 (biotinylated 11B1 Fab) was used as a negative control for inhibition of platelet aggregation. Cross-linking of receptors was induced by 10 g/mL Neutravidin, resulting in either platelet aggregation or inhibition.
HITS-mediated platelet aggregometry
The assay system used was essentially the same as that in Fc␥RIIa-mediated platelet aggregation studies using aggregated human IgG. However, HITS-positive donor sera along with 1 U/mL heparin instead of aggregated IgG were used to induce platelet aggregation. A volume of 450 L of 3 ϫ 10 6 /mL PRP with 20 L HITS-positive donor sera and 1 U/mL heparin were used in these experiments. 8 /mL) in RCD, pH 6.5, containing 0.2% (vol/vol) bovine serum albumin (BSA) were incubated with the respective donor and acceptor fluorochrome-labeled F(ab)Ј 2 fragments directed to the receptors at 10 g/mL for 20 minutes. Samples were then centrifuged for 1500g for 5 minutes at room temperature, then washed with 200 L RCD, pH 6.5, containing 0.2% (wt/vol) BSA and resuspended in 0.5 mL RCD, pH 7.4, for FRET detection by using an LS-50B luminescence spectrometer (Perkin Elmer, Bucks, England).
Calcium mobilization
Washed platelets (4 mL of 3 ϫ 10 8 cells/mL) in RCD, pH 6.5, were loaded with 3 M fluorescent calcium indicator, Fura-2/AM (Molecular Probes) as previously described. 28 To induce calcium mobilization, 5 g/mL biotinylated IV.3 IgG was added and allowed 5 minutes for binding prior to the addition of 10 g/mL Neutravidin to induce clustering of Fc␥RIIA. Biotinylated anti-PECAM-1 Fab and a negative control biotinylated anti-CD151 Fab at 5 g/mL were used for coengagement of PECAM-1 and CD151 as required.
IV.3 cross-linking with and without PECAM-1 coengagement and immunoprecipitation/Western blot studies
A volume of 0.5 mL washed human platelets (3 ϫ 10 8 /mL) in RCD, pH 7.4, was stirred at 200g in an aggregometer cuvette at 37°C for 1 minute in a Payton dual channel aggregometer module (Paton Scientific, Victor Harbour, South Australia). Biotinylated IV.3 IgG (10 g/mL) was then added and allowed to bind to the platelets for 5 minutes before cross-linking by the addition of 10 g/mL Neutravidin. For PECAM-1 coengagement, 10 g/mL biotinylated anti-PECAM-1, 2BD4, or PECAM-1.1 Fab fragments were added after the addition of biotinylated IV.3 IgG. Samples were cross-linked with 10 g/mL Neutravidin for 0, 15 seconds, 30 seconds, 1 minute, 2 minutes, 5 minutes, and up to 15 minutes before stopping the reaction with the addition of 0.5 mL Triton lysis buffer. Specific details of immunoprecipitation procedures, Western blotting, and stripping are as previously described. 16 
Chemical cross-linking of cell surface antigens and digitonin lysis of platelet preparations
Chemical cross-linking of platelet cell surface antigens and digitonin lysis conditions are essentially as previously described. 18 Following lysis, samples were centrifuged at 11 000g for 10 minutes at 4°C, and digitoninsoluble supernatants were removed for preclearing and immunoprecipitation studies.
Statistical analysis of data
Acquisition flow cytometry analysis data were analyzed statistically with Excel (Microsoft, Redmond, WA) for statistical significance using Student t test (P Ͻ .05 as significant), standard deviation, and error.
Results
Effect of mAbs on aggregated human IgG and IV.3 binding to platelets
To establish a possible physical proximity relationship between Fc␥RIIa and PECAM-1, aggregated IgG binding to Fc␥RIIa studies were conducted in the presence and absence of anti-PECAM-1 Fab fragments. These studies have revealed significant reduction (P Ͻ .05) of binding of aggregated IgG (75 g/mL) to Fc␥RIIa with treatment of platelets with 4 different anti-PECAM-1 Fab fragments (PECAM-1.1 and PECAM-1.3, B2B1 and 2BD4) ( Figure 1A ). Specifically, a 2.5-fold reduction in aggregated IgG binding was observed following pretreatment with anti-PECAM-1 Fab fragments, whereas a 6-fold decrease in aggregated IgG binding to Fc␥RIIa was observed with Fc␥RIIa-specific blocking mAb, IV.3 Fab (10 g/mL). Conversely, pretreatment with an antibody recognizing a platelet tetraspanin family member, CD151, had no observable effect in terms of inhibition of aggregated IgG binding. CD151 has a similar copy number to PECAM-1 on platelets on the basis of 11B1 binding. 23 To exclude the possibility that anti-PECAM-1 Fab fragments interfere with Fc␥RIIa ligand binding, we performed a doseresponse of nonbiotinylated anti-PECAM-1 Fab fragments (0-40 g/mL) in the presence of biotinylated IV.3 Fab fragments and detected IV.3 binding to platelets with streptavidin-phycoerythrin (PE) and flow cytometry. As shown in Figure 1B , the anti-PECAM-1 Fab fragments had no effect on the alteration of the IV.3 binding to Fc␥RIIa on the platelet membrane. Overall, these results suggest the existence of either a close physical or functional proximity between Fc␥RIIa and PECAM-1, whereas no such relationship can be observed between Fc␥RIIa and CD151.
Analysis of receptor colocalization by FRET
On the basis of the ability of anti-PECAM-1 mAbs to inhibit the binding of aggregated human IgG to washed human platelets, we For personal use only. on October 16, 2017 . by guest www.bloodjournal.org From hypothesized that PECAM-1 and Fc␥RIIa were located in close physical proximity on the platelet membrane. To test the proximity we used FRET between antibodies bound to Fc␥RIIa and PE-CAM-1 and coimmunoprecipitation studies. By using FITCconjugated anti-Fc␥RIIa IV.3 F(abЈ) 2 and Alexa Fluor 546-conjugated anti-PECAM-1.1 as the donor and acceptor fluorochromes, respectively, significant (100%) FRET was observed relative to background controls (Figure 2 ). FITC-conjugated antiFc␥RIIA IV.3 F(abЈ) 2 and Alexa Fluor 546-conjugated anti-GPIb␣ VM16d was also positive (100%) for FRET as shown previously (Figure 2 ). 18 Relatively lower FRET (6%-20%) was observed with donor and acceptor fluorochromes labeling of the same receptor for all 3 receptors (Figure 2 ), indicating the proximity of Fc␥RIIa to PECAM-1 and to GPIb␣ is much greater than that between identical receptors.
Physical association between Fc␥RIIa and PECAM-1
Immunoprecipitation with anti-PECAM-1.1 and anti-Fc␥RIIa IV.3 IgG mAbs from chemically cross-linked and non-cross-linked digitonin-lysed platelets and blotting for PECAM-1 reveals the presence of PECAM-1 bands ( Figure 3A ). In contrast, platelet lysates immunoprecipitated with healthy mouse IgG 1 and anti-CD151, 11B1.G4 IgG mAb, displayed no PECAM-1 bands. Conversely, when similarly treated platelet lysates were blotted for CD151 with 11B1.G4 IgG mAb, only anti-CD151, 11B1.G4 immunoprecipitates displayed the presence of CD151 ( Figure 3B ). In addition, cross-linking decreased the yield of monomeric PECAM-1 but induced the formation of dimeric and oligomeric forms of PECAM-1 (results not shown) in both digitonin-lysed platelets immunoprecipitated with anti-PECAM-1 and antiFc␥RIIa mAb, as previously described. 29 Taken as a whole, these results indicate that Fc␥RIIa is constitutively associated with PECAM-1, whereas CD151 is not physically associated with either receptor, on the platelet membrane.
Effect of mAbs on aggregated IgG-mediated platelet aggregation
Whereas aggregated human IgG induced rapid and robust platelet aggregation, there was complete inhibition of aggregated IgGinduced platelet aggregation following pretreatment of washed platelets with anti-PECAM-1 IgG mAb, PECAM-1.1 ( Figure 4) . Similar results were obtained with anti-PECAM-1 mAbs, 2BD4 and B2B1 (results not shown). Similarly, the anti-Fc␥RIIa, IV.3
IgG mAb (10 g/mL) displayed the same inhibitory outcome ( Figure 4A ). Conversely, as predicted from initial inhibition of aggregated IgG binding studies, anti-CD151, 11B1.G4 mAb IgG, does not inhibit platelet aggregation ( Figure 4A ). To exclude any Fc-mediated effects, Fab fragments were used in subsequent platelet experiments. Pretreatment with biotinylated anti-PECAM-1 Fab (2BD4) (10 g/mL) and cross-linking of PECAM-1 with Neutravidin (10 g/mL) results in inhibition of aggregated IgG-induced platelet aggregation ( Figure 4B ). Nonbiotinylated anti-Fc␥RIIA F(ab) (IV.3) exhibits potent inhibition of platelet aggregation, whereas no inhibition of platelet aggregation is observed with biotinylated anti-CD151 Fab (11B1.G4) (10 g/mL) ( Figure 4B ). This inhibitory effect mediated by anti-PECAM Fab fragments on Fc␥RIIa-mediated platelet aggregation required cross-linking of PECAM-1.
Effect of mAbs on Fc␥RIIa-mediated platelet aggregation
Fc␥RIIa-mediated platelet aggregation was performed using biotinylated IV.3 mAb (10 g/mL) and cross-linking with Neutravidin (10 g/mL). The addition of biotinylated anti-PECAM-1 Fab (2BD4) prior to cross-linking with Neutravidin allows the simultaneous coengagement of PECAM-1. Coengagement of PECAM-1 induced by addition of biotinylated anti-PECAM-1 Fab (2BD4) with biotinylated IV.3 mAb followed by cross-linking with Neutravidin resulted in a dose-dependent inhibition of platelet aggregation with biotinylated 2BD4 anti-PECAM-1 Fab fragments ( Figure  5A ). Conversely, when biotinylated anti-CD151 Fab (11B1.G4) was used to simultaneously cross-link CD151 and Fc␥RIIa, no inhibition of platelet aggregation was observed ( Figure 5B) . Similarly, in the absence of Neutravidin, no platelet aggregation response was observed, signifying the specificity of biotinylated anti-PECAM-1 Fab to inhibit Fc␥RIIa-mediated platelet aggregation ( Figure 5B ).
Effect of mAbs on HITS-mediated platelet aggregation
In humans, the sole Fc receptor for IgG, Fc␥RIIa, in platelets plays an important role in the pathophysiology of drug-induced thrombocytopenia, including HITS. On the basis of these features, we hypothesized that PECAM-1 may negatively regulate HITSmediated platelet aggregation via its down-regulation of Fc␥RIIa-mediated signaling events. To test this possibility, we examined the effect of anti-PECAM-1 Fab fragments in HITS-mediated platelet aggregation. As shown in Figure 6 , 3 ϫ 10 8 washed platelets/mL pretreated with 10 g/mL biotinylated anti-PECAM-1 Fab fragments (2BD4) and cross-linking with 10 g/mL Neutravidin resulted in 5-fold inhibition of platelet aggregation induced by 20 L HITS-positive donor sera. Similar results were observed with anti-PECAM-1 Fab fragments, PECAM-1.1 and B2B1 (results not shown). In addition, pretreatment with nonbiotinylated antiFc␥RIIa Fab fragments (IV.3) (10 g/mL) also inhibited HITSmediated platelet aggregation ( Figure 6 ). In contrast, no inhibitory effect was observed with biotinylated anti-CD151 Fab fragments (11B1.G4) (10 g/mL). Taken together, these studies strongly suggest the negative inhibitory effect of PECAM-1 activation on Fc␥RIIa-mediated platelet aggregation induced by HITS antibodies.
Coengagement of Fc␥RIIa and PECAM-1 leads to negative regulation of phospholipase C␥2 and PI 3-kinase-dependent signaling pathways
On clustering, Fc␥RIIa is tyrosine phosphorylated and recruits Syk protein-tyrosine kinase (PTK) via its intrinsic ITAMs The recruitment of Syk PTK allows tyrosine phosphorylation of PLC␥2 and recruitment of phosphatidylinositol 3 (PI 3) kinase, whose activation results in downstream rapid accumulation of phosphatidylinositol-3, -4, -5 phosphate [PtdIns(3,4,5)P 3 ] and Akt phosphorylation. Activation of the PLC␥2 signaling pathway results in calcium mobilization to promote platelet secretion and engagement of integrin ␣ IIb ␤ 3 to initiate platelet aggregation. On the basis of our studies with PECAM-1, we hypothesize that coengagement of PECAM-1 and its recruitment and activation of protein-tyrosine Figure 6 . Inhibition of Fc␥RIIa-mediated HITS platelet aggregation by crosslinked anti-PECAM-1 Fab fragments. Platelet-rich plasma (3 ϫ 10 6 platelets/mL) was pretreated with various biotinylated Fab antibody fragments directed to CD151 (11B1) (10 g/mL); nonbiotinylated anti-Fc␥RIIa (IV.3) (10 g/mL), and anti-PECAM-1 (2BD4) (10 g/mL) for 5 minutes prior to cross-linking with 10 g/mL Neutravidin and stimulation with HITS-positive donor sera and 1 U/mL heparin to induce HITS-mediated platelet aggregation. For personal use only. on October 16, 2017. by guest www.bloodjournal.org From phosphatases such as SHP-2 delivers a negative feedback signal to down-modulate Fc␥RIIa-mediated signaling events. To test this hypothesis, we examined a number of phosphorylation profiles of key signaling molecules (antiphosphotyrosine content, tyrosine phosphorylation of PLC␥2, phosphoSer/Thr Akt) and calcium mobilization associated with Fc␥RIIa signaling by using immunoprecipitation, Western blot, and calcium mobilization studies.
The antiphosphotyrosine blot of total tyrosine phosphorylated platelet proteins following IV.3 cross-linking of Fc␥RIIA alone or with PECAM-1 coengagement revealed induction of several tyrosine phosphorylated platelet proteins following clustering of Fc␥RIIA alone ( Figure 7A, lanes 1-6) . In contrast, coengagement of PECAM-1 with Fc␥RIIA cross-linking induced a significant reduction in tyrosine phosphorylation over time of at least 4 identifiable tyrosine phosphorylated platelet proteins as indicated by arrows with approximate molecular weights of p64, p55, p45, and p40 ( Figure 7A, lanes 8-13) . After 1 minute of coengagement with PECAM-1, a significant decrease in tyrosine phosphorylation of these 4 platelet proteins was seen, as observed in lanes 12 and 13. Three of the 4 platelet proteins displayed inducible proteintyrosine phosphorylation subsequent to clustering of Fc␥RIIa after 15 seconds with IV.3 cross-linking as indicated in lanes 2 to 6 ( Figure 7A ). Overall, these results indicate a reduction in tyrosine phosphorylation of platelet proteins on PECAM-1 coengagement consistent with its inhibitory activity.
Protein-tyrosine phosphorylation is an early event in Fc␥RIIa-mediated signal transduction. To test if PECAM-1 cross-linking attenuated Fc␥RIIa-mediated signal transduction, we performed a time course (0-5 minutes) of IV.3 Ϯ PECAM-1 cross-linking, lysed the platelet suspensions, immunoprecipitated PECAM-1, and detected tyrosine phosphorylated PECAM-1 by immunoblotting with an antiphosphotyrosine antibody, RC20. As shown in Figure 7B (top panel), weak inducible tyrosine phosphorylation of PECAM-1 was observed following IV.3 cross-linking over time (lanes 1-6) and strongly inducible after 15 seconds following IV.3 Ϯ PECAM-1 (lanes 8-13) . Cross-linking of PECAM-1 alone with mAbs results in weak inducible tyrosine phosphorylation of PECAM-1 as previously described. 28 In addition, as shown in Figure 7B (middle panel), inducible recruitment of SHP-2 proteintyrosine phosphatase parallels the induction of tyrosine phosphorylation of PECAM-1 observed over time. The anti-PECAM-1 blot confirmed the proper PECAM-1 antigen loading in PECAM-1 immunoprecipitates ( Figure 7B, bottom panel) . These studies verify that induction of the tyrosine phosphorylation of PECAM-1 ITIMs leads to the recruitment of SHP-2 following clustering of Fc␥RIIa and PECAM-1 in platelets.
As recruitment of Syk by Fc␥RIIa leads to recruitment of PLC␥2 and subsequent downstream activation of signaling events, we tested the tyrosine phosphorylation status of PLC␥2 following clustering of Fc␥RIIA and coengagement of Fc␥RIIa and PE-CAM-1. As shown in Figure 8A (top panel), following clustering of Fc␥RIIa, there is an inducible tyrosine phosphorylation of PLC␥2 evident at 30 seconds and peaking at 1 minute. Following coengagement of Fc␥RIIa and PECAM-1, there was almost complete inhibition of the tyrosine phosphorylation of PLC␥2 (lanes 9-13). In contrast, coengagement of Fc␥RIIa and CD151 showed no difference in the level of tyrosine phosphorylation of PLC␥2 ( Figure 8B, top panel) . PLC␥2 antigen loading is consistent in all lanes ( Figure 8A-B, bottom panels) . To exclude the possibility that competition between biotinylated anti-IV.3 and biotinylated anti-PECAM-1 Fab fragments for a limiting amount of Neutravidin accounts for the lower level of tyrosine phosphorylated PLC-␥2 over time, we have performed a dose response of Neutravidin (0-100 g/mL) at a 1 minute timepoint. As shown in Figure 8C , increasing doses of Neutravidin resulted in equivalent levels of tyrosine phosphorylation of PLC-␥2 following IV.3 cross-linking alone. Following cross-linking of IV.3 and PECAM-1, the reduced tyrosine phosphorylation of PLC-␥2 is not affected by supersaturating concentrations of Neutravidin. These studies have shown that coengagement of PECAM-1 with Fc␥RIIa leads to dephosphorylation of tyrosine phosphorylated PLC␥2, an inhibitory signaling event characteristic of PECAM-1-mediated signaling involving SHP-2 recruitment and activation.
In addition, as recruitment of Syk by Fc␥RIIa also leads to recruitment of PI 3-kinase and subsequent downstream activation of signaling events, we tested the Ser/Thr phosphorylation status of Akt, a known downstream effector of PI 3-kinase-dependent signaling events following coengagement of Fc␥RIIa and PECAM-1. Following clustering of Fc␥RIIa, there is an inducible Ser/Thr phosphorylation of Akt evident by 30 seconds of stimulation ( Figure 9A, lanes 3-6) . In contrast, there was complete inhibition of Ser/Thr phosphorylation of Akt following coengagement of PECAM-1 with Fc␥RIIa and probing with antiphosphoSer/Thr Akt (lanes 9-13). Equal protein loading is observed in an Akt Western blot ( Figure 9B ). These results most likely suggest that recruited SHP-2 dephosphorylates Syk, an essential upstream effector of PI 3-kinase recruitment and activation by Fc␥RIIa, thereby initiating a block in PI 3-kinase-dependent signaling events.
As recruitment of Syk by Fc␥RIIa leads to tyrosine phosphorylation of PLC␥2, generation of secondary messengers inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG) and subsequent calcium mobilization, we tested the effect on calcium mobilization following coengagement of Fc␥RIIa and PECAM-1. Following IV.3 cross-linking, there was release of calcium from intracellular stores. In contrast, coengagement of PECAM-1 with Fc␥RIIa resulted in inhibition of intracellular calcium release, whereas coengagement of CD151 with Fc␥RIIa cross-linking displayed no inhibitory effect (Figure 10 ). Inactivation of PLC␥2 leading to inhibition of Ca 2ϩ mobilization is likely to be mediated on PECAM-1 inhibitory signaling involving down-regulation of phosphorylation of PLC␥2 by Syk, decrease in PIP 3 (PI 3-kinase, phosphatidylinositol 3,4,5-trisphosphate) production as a result of down-regulation of PI 3-kinase activity.
Discussion
The concept that ITIM-bearing molecules have the capacity to negatively regulate cell activation induced by coaggregation with receptors bearing ITAMs has been demonstrated in a variety of immune cells. In human platelets, 2 different ITAM-associated receptor complexes are known. These receptors are the collagen GPVI receptor noncovalently coupled to a signal receptor ITAMcontaining molecule, FcR-␥ chain, and Fc␥RIIa containing an intrinsic ITAM in its intracellular domain. On the basis of this study, we have demonstrated that PECAM-1 and Fc␥RIIa are located in close physical proximity and are colocalized on the platelet membrane. This novel observation is supported by functional studies with PECAM-1-mediated signaling events inducing negative regulation of Fc␥RIIa-mediated signaling events and Fc␥RIIa-mediated platelet aggregation. From a clinical perspective, we found that PECAM-1 is an important negative regulator of HITS-mediated platelet aggregation via its potent inhibition of Fc␥RIIa-mediated signaling events.
There are several examples of physical associations of platelet receptors on the platelet membrane that have been described, including GPIb␣ association with Fc␥RIIa 18 and GPIb␣ association with protein-disulfide isomerase. 19 On the basis of this study, we have shown the existence of a close physical relationship between Fc␥RIIa and PECAM-1 with potent inhibition of aggregated IgG binding with all 4 anti-PECAM-1 mAb Fab fragments For personal use only. on October 16, 2017 . by guest www.bloodjournal.org From directed to various Ig-domains. In contrast, no physical relationship between Fc␥RIIa and CD151 was established with anti-CD151 mAb Fab, 11B1.G4. Other physical studies using FRET and coimmunoprecipitation further supported the concept of a physical relationship and colocalization of these 2 receptors on the platelet plasma membrane. The FRET-based analysis indicated that Fc␥RIIa and PECAM-1 are located in close physical proximity as required for energy transfer to occur. The coimmunoprecipitation studies with and without chemical cross-linking using membrane impermeable, DTSSP (3,3Ј-dithiobis(sulfosuccinimidyl propionate)), revealed that Fc␥RIIa and PECAM-1 are constitutively associated on the platelet membrane under resting conditions. This interaction on an activated platelet may lead to Fc␥RIIa influencing conformational changes in PECAM-1, or vice versa, to modulate ligand binding properties. Again, no such relationship appears to exist between Fc␥RIIa and CD151.
The sensitivity of FRET in a system in which both donor and acceptor fluorochromes are used is known to be dependent on a number of factors. These factors include relative receptor density of the 2 receptors under analysis, brightness of donor and acceptor fluorochromes with preferential overlapping of the emission, and absorption peaks of the donor and acceptor fluorochromes, respectively, and relative distribution of receptors on the platelet membrane. The Forster upper limit of critical distance for energy transfer (8-10 nm) is dependent upon the donor and acceptor pair and on the distance between fluorochromes attached to respective antigens. On the basis of estimates of copy number, the density difference between PECAM-1 and Fc␥RIIa is approximately 5 to 1. Taking these factors into consideration, we used the lower density Fc␥RIIa as the donor and the higher density PECAM-1 as the acceptor.
One could also argue that the significant FRET observed with PECAM-1 and Fc␥RIIa labeled acceptor and donor fluorochromes may be due to an artifact of high receptor density, whereby FRET is due to chance association rather than true physical proximity. This association can be ruled out, as it can be calculated that one molecule of PECAM-1 would be found in an area of 1800 nm 2 from the statistics of 10 000 copies of PECAM-1 on 22 m 2 area of a platelet surface. On the assumption of even receptor distribution in a lattice-like arrangement, receptors are, therefore, estimated to be 60 nm apart, much greater than the required Forster upper limit of 8 to 10 nm for FRET. The chance of random FRET with respect to Fc␥RIIa is even lower given the 5-fold lower density. In addition, our results of FRET between the same receptor were significantly lower than that between Fc␥RIIa and PECAM-1, and Fc␥RIIa and GPIb␣, indicating that homoassociation of receptors leading to FRET was not significant.
Functional studies using 3 different approaches involving aggregated IgG, biotinylated IV.3 mAb IgG cross-linking of Fc␥RIIa, and HITS antibody-induced platelet aggregation indicated the potent inhibitory functional effects of anti-PECAM-1 Fab fragments in negatively regulating Fc␥RIIa-mediated platelet aggregation. In contrast, the tetraspanin family member, CD151, was observed to have no functional relationship with Fc␥RIIa. These 3 different approaches have different mechanisms of activation of Fc␥RIIa to induce platelet aggregation. The use of a more specific and potent method involving the cross-linking of Fc␥RIIa with or without PECAM-1 engagement using biotinylated antiFc␥RIIa Fab and biotinylated anti-PECAM-1 Fab and Neutravidin have shown consistent inhibitory activity of PECAM-1 on Fc␥RIIa-mediated platelet aggregation. For this reason, this method was used in subsequent Ca 2ϩ mobilization and signaling studies.
Numerous in vitro studies have concluded that antibodies to the heparin:PF4 complex activate human platelets via Fc␥RIIa. [30] [31] [32] [33] In this study, we provide evidence that platelet aggregation induced by HITS antibodies is mediated by Fc␥RIIa in vitro as revealed by the inhibition of platelet aggregation by intact and Fab antiFc␥RIIa mAb, IV.3, in both washed platelets and plasma-rich plasma. More significantly, activation of PECAM-1 using anti-PECAM-1 intact mAb and Neutravidin biotinylated anti-PECAM-1 Fab inhibited platelet aggregation, whereas anti-CD151 Fab fragments had no effect. Because PECAM-1 can negatively modulate collagen GPVI-dependent signaling events involving the FcR-␥ chain 1,2 and Fc␥RIIa as revealed in this study, it is possible that the same mechanism of inhibition involving activation of PECAM-1 and its ITIM coinhibitory signaling pathways is involved in inhibition of HITS antibody-induced ITAM-containing Fc␥RIIa-mediated platelet aggregation.
To define the molecular mechanisms of PECAM-1-mediated negative regulation of Fc␥RIIa-mediated platelet responses, we analyzed the profiles of signaling molecules associated in Fc␥RIIa-mediated signaling pathways. We hypothesized that PECAM-1 may negatively regulate the Fc␥RIIa-mediated signaling pathway on its activation, phosphorylation of its dual ITIMs, recruitment and activation of SHP-2 protein-tyrosine phosphatase, and subsequent dephosphorylation of multiple key proteins involved in Fc␥RIIa-mediated signaling pathway. Our studies show that PE-CAM-1 coengagement in Fc␥RIIa-mediated signaling results in inducible tyrosine phosphorylation of the dual PECAM-1 ITIMs, recruitment of SHP-2, 34 and dephosphorylation of protein-tyrosine signaling species known to be involved in this signaling pathway, including PLC␥2, 35 Akt, and inhibition of Ca 2ϩ mobilization. These signaling events are a prerequisite for integrin ␣ IIb ␤ 3 activation and platelet aggregation. Taken together, these results provide further evidence of the inhibitory role of PECAM-1 in Fc␥RIIa-mediated platelet aggregation.
However, there is current controversy in relation to recent findings about the actual role of SHP-2. Unlike SHP-1 proteintyrosine phosphatase, which primarily acts as a negative regulator, SHP-2 can act as a positive or negative regulator in cell signaling, depending on the cell type and signaling complexes formed. 36, 37 These 2 closely related SH2 domain-containing protein-tyrosine phosphatases have been demonstrated to display differential substrate specificity, including the Ig-ITIM family member, SIRP␣. 38 Recently, SHP-2 has been shown to negatively regulate the kinetics and amplitude of PI 3-kinase activation in a receptor-specific manner. 39 Several studies have highlighted differences in the functional regulation mediated by SHP-2. In fibroblast cell lines, SHP-2 acts as a positive regulator of PI 3-kinase activation by insulin growth factor 1 (IGF-1) or insulin. In contrast, in similar cell lines, SHP-2 can act as a negative regulator of epidermal growth factor (EGF)-induced PI 3-kinase activation. In platelet studies, SHP-2 appears to play a negative regulatory role in collagen GPVI activation. PECAM-1-deficient platelets showed hyperresponsive features of collagen GPVI/FcR-␥ chain-mediated responses and increased platelet thrombus formation on type I collagen and preferential recruitment of SHP-2 by phosphorylated PECAM-1 ITIMs in platelet signaling. 1, 2 Overall, on the basis of our findings, there is strong evidence that a physical and functional relationship between Fc␥RIIa and PECAM-1 exists on the surface of human platelets. The implications of these findings are of relevance in scientific and clinical terms. First and foremost, Fc␥RIIa, with its ITAM associated with the ligand-binding polypeptide, has not been demonstrated to be regulated by PECAM-1 on platelets. In addition, the novel findings of the colocalization of Fc␥RIIa and PECAM-1 on human platelets, albeit probably only existing in approximately 10% of the PECAM-1 receptor population, on human platelets is quite unexpected. Fc␥RIIa has been demonstrated in our and numerous in vitro studies to be a very potent mediator of platelet activation, secretion, and aggregation. From this perspective, PECAM-1 may have a role in functional regulation of Fc␥RIIa-mediated events in platelets in vivo. In particular, Fc␥RIIa has been demonstrated to be involved in immune complex-mediated phagocytosis of platelets by macrophages and in high IgG content sites such as in inflammation. 40, 41 From a clinical point of view, Fc␥RIIa has been implicated in immune complex-mediated diseases such as systemic lupus erythematosus (SLE) and heparin-induced thrombocytopenia and/or thrombosis (HITTS). 42, 43 Specifically, our findings show that PECAM-1 can abrogate Fc␥RIIa-mediated HITS antibody-induced platelet aggregation. These in vitro studies provide a foundation to explore the consequences of PECAM-1-negative regulation of Fc␥RIIa-mediated signaling events within the context of in vivo disease models, including HITS.
